Publications by authors named "Patrick Trunet"
Background: It is documented that omalizumab treatment reduces the cell surface expression of immunoglobulin E high-affinity receptor (FcɛRI) on several cell types. This has not been investigated in patients with uncontrolled severe persistent allergic asthma.
Methods: In a double-blind, randomized, placebo-controlled study, patients with severe allergic asthma uncontrolled by high dose inhaled corticosteroids and long-acting β(2)-agonist received either omalizumab (n = 20) or placebo (n = 11) over 16 weeks at appropriate doses and frequencies.
Article Synopsis
- The study found that the beta-blocker atenolol is less effective than angiotensin-receptor blockers (like valsartan) and calcium-channel blockers (like amlodipine) in reducing central blood pressure in patients with resistant hypertension.
- A clinical trial with 393 patients showed that the combination of amlodipine and valsartan significantly reduced central systolic blood pressure by 13.70 mm Hg compared to a 9.70 mm Hg reduction with atenolol.
- The study also indicated that while heart rate decreased more with the atenolol combination, overall central blood pressure measurements and augmentation index were still significantly better with the amlodipine-valsartan combination, suggesting greater cardiovascular benefits.